Amount receivable upon achievement of milestone by entity under research and development agreement.

No definition available.

Name:	opht_ResearchAndDevelopmentArrangementAggregateAmountReceivableUponAchievementOfMilestone
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the amount of patient enrollment-based milestone revenue achieved by the entity.

+ References

No definition available.

+ Details

Name:	opht_ResearchAndDevelopmentArrangementAmountOfEnrollmentBasedMilestoneAchieved
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of upfront fees received under the agreement.

+ References

No definition available.

+ Details

Name:	opht_ResearchAndDevelopmentArrangementUpfrontFeesReceived
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=opht_LicensingAndCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Licensing and Commercialization Agreement with Novartis Pharma AG (Details) (Novartis Pharma AG, USD $) In Millions, unless otherwise specified	1 Months Ended		12 Months Ended	0 Months Ended
	Sep. 30, 2014	May 31, 2014	Dec. 31, 2014	May 19, 2014
Agreement
Upfront fees received		$ 200.0	$ 200.0
Patient enrollment-based milestone revenue achieved	50.0
Licensing and Commercialization Agreement
Agreement
Upfront fees received				200.0
Licensing and Commercialization Agreement \| API transfers
Agreement
Recognized revenues			0.9
Licensing and Commercialization Agreement \| Achievement of specified patient enrollment milestones
Agreement
Patient enrollment-based milestone revenue achieved	50.0
Recognized revenues			41.3
Licensing and Commercialization Agreement \| Achievement of specified patient enrollment milestones \| Maximum
Agreement
Aggregate amount receivable on achievement of milestone			130.0
Licensing and Commercialization Agreement \| Achievement of specified patient enrollment milestones \| Licensing activities
Agreement
Recognized revenues			38.4
Licensing and Commercialization Agreement \| Achievement of specified patient enrollment milestones \| Research and development activity revenue
Agreement
Recognized revenues			2.0
Licensing and Commercialization Agreement \| Achievement of specified regulatory approval milestones \| Maximum
Agreement
Aggregate amount receivable on achievement of milestone			300.0
Licensing and Commercialization Agreement \| Achievement of specified commercial sale milestone \| Maximum
Agreement
Aggregate amount receivable on achievement of milestone			$ 400.0